COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

PI-88 in Hepatocellular Carcinoma After Hepatectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00247728
Recruitment Status : Completed
First Posted : November 2, 2005
Last Update Posted : October 18, 2007
Medigen Biotechnology Corporation
Information provided by:
Progen Pharmaceuticals

Tracking Information
First Submitted Date  ICMJE November 1, 2005
First Posted Date  ICMJE November 2, 2005
Last Update Posted Date October 18, 2007
Study Start Date  ICMJE June 2004
Primary Completion Date Not Provided
Current Primary Outcome Measures  ICMJE
 (submitted: November 1, 2005)
Tumour non-recurrence rate
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: November 1, 2005)
  • Time to first recurrence
  • Survival rate
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
Descriptive Information
Brief Title  ICMJE PI-88 in Hepatocellular Carcinoma After Hepatectomy
Official Title  ICMJE A Randomized, Multi-Centre, Efficacy Evaluation of PI-88 in Patients With Hepatocellular Carcinoma After Hepatectomy - A Phase II Study
Brief Summary The purpose of this study is to evaluate the efficacy of PI-88 to inhibit or reduce tumor recurrence in patients with hepatocellular carcinoma following hepatectomy.
Detailed Description

Although early diagnosis and treatment improve survival, hepatocellular carcinoma (HCC) is rarely cured and recurs frequently after regional therapy or transplantation. Hepatic resection can improve 5-year recurrence-free survival by up to 25%. Micrometastases of HCC have been detected by molecular techniques in 88% of patients at the time of surgery, and probably cause postoperative recurrence. Efforts to reduce the risk of recurrence after a curative resection have been tried, including various regimens of adjuvant and neoadjuvant therapy.

In this study , an anti-angiogenic agent, PI-88, is being used as an adjuvant therapy for HCC patients after curative hepatic resection. The efficacy endpoints, including tumour non-recurrence rate, time to first recurrence and 1-year survival rate are being evaluated. Several risk factors associated with tumour recurrence are also being analysed.

There are two stages to this study. In stage 1 there are three arms - untreated control and two arms are two different PI-88 dose. In stage 2 the better of the two PI-88 arms will be continued against the control arm.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Carcinoma, Hepatocellular
Intervention  ICMJE Drug: PI-88
Study Arms  ICMJE Not Provided
Publications *

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE
 (submitted: November 1, 2005)
Original Enrollment  ICMJE Same as current
Study Completion Date  ICMJE June 2008
Primary Completion Date Not Provided
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients have voluntarily given written informed consent
  • Age ≥ 18 years but ≤ 75 years
  • Males or females
  • Histological diagnosis of hepatocellular carcinoma
  • Curative hepatectomy within the past 4-6 weeks
  • ECOG performance status of 0 to 2
  • Cardiac functional capacity ≤ to class II (New York Heart Association)
  • Patients with adequate renal, hepatic, and haematopoietic function as defined by:

    • Serum creatinine ≤ 2.0 mg/dL
    • Total bilirubin < 2.5 mg/dL
    • Neutrophil count > 1.5 x 10^9/L
    • ALT < 5 x upper limit of normal (ULN)
    • White blood cell (WBC) count ≥ 3 x 10^9/L
    • Platelet count ≥ 80 x 10^9/L
    • Prothrombin time international normalized ratio (PT-INR) ≤ 1.3 (or PT-INR ≤ 1.4 but PT within normal range)
    • Activated partial thromboplastin time (APTT) < ULN

Exclusion Criteria:

  • Patients with history of allergy and/or hypersensitivity to anticoagulants/thrombolytic agents, especially heparin.
  • Patients with history of immune mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or other platelet disease
  • Patients with previous positive result in a heparin-induced thrombocytopenia (HIT) antibody test.
  • Patients with any tumour metastasis.
  • Patients with uncontrolled infection or serious infection within the past 4 weeks.
  • Patients with myocardial infarction, stroke, or congestive heart failure within the past 3 months.
  • Patients with history of inflammatory bowel disease, any other abnormal bleeding tendency, or patients at risk of bleeding due to open wounds or planned surgery.
  • Patients with acute or chronic gastrointestinal bleeding within the past 1 year.
  • Patients with a history of drug abuse or psychiatric disorder.
  • Patients with known HIV infection or AIDS-related illness.
  • Patients who received other investigational or anti-neoplastic medication within the past 4 weeks.
  • Use of aspirin, aspirin-containing medications, non-steroidal anti-inflammatory drugs (except for COX-2 inhibitors), heparin, low molecular weight heparin, warfarin, anti-platelet drugs, or any other anticoagulant medications 2 weeks prior to or during the study period.
  • Women who are pregnant or breast-feeding.
  • Women of child-bearing potential who are not using an adequate method of contraception.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Taiwan
Removed Location Countries  
Administrative Information
NCT Number  ICMJE NCT00247728
Other Study ID Numbers  ICMJE MG 002
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Progen Pharmaceuticals
Collaborators  ICMJE Medigen Biotechnology Corporation
Investigators  ICMJE
Principal Investigator: Pei-Jer Chen, MD, PhD National Taiwan University Hospital
PRS Account Progen Pharmaceuticals
Verification Date October 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP